Article Text


Pregnancy in past or present lupus nephritis: a study of 32 pregnancies from a single centre


OBJECTIVE To study maternal and fetal outcome in women with past or present histologically proven systemic lupus erythematosus (SLE) nephritis.

METHOD Retrospective study of 32 pregnancies in 22 women with past or present histologically proven SLE nephritis in a single French centre.

RESULTS Pregnancy (25 planned and 7 not planned) occurred in a mean (SD) of 8 (5) years after SLE diagnosis and 6 (4) years after renal disease onset. Seven occurred in women with antiphospholipid syndrome. At pregnancy onset, all but one woman had creatininaemia below 100 μmol/l, five had proteinuria >0.5 g/day, none had hypertension. Twelve pregnancies occurred in women previously treated with immunosuppressant drugs. Treatment comprised prednisone (n=31), hydroxychloroquine (n=11), aspirin (n=22), heparin (n=12), and azathioprine in one patient with steroid resistant nephrotic syndrome disclosing SLE. No therapeutic abortion was done. During pregnancy or the postpartum period, or both, proteinuria >0.5 g/day occurred in 10 women (five related to pre-eclampsia, four to renal flare, one to stable nephrotic syndrome). One flare consisted of mild arthralgias. Pregnancy outcome comprised one feto-maternal death in SLE disclosed by pregnancy, five embryonic losses, two fetal deaths, and 18 premature (one neonatal death) and six full term births. No criterion appeared to influence fetal survival significantly. At long term, one patient died during an SLE flare, three women had renal relapses. At the last visit, all had creatininaemia below 100 μmol/l except one woman with creatinine level 115 μmol/l, nine had proteinuria >0.5 g/day, and one was treated for hypertension.

CONCLUSION Pregnancy need not be discouraged in women with a history of SLE nephritis with normal or mildly impaired renal function. Deterioration of renal function rarely occurs. However, these pregnancies are at high risk of pre-eclampsia and prematurity.

  • systemic lupus erythematosus
  • pregnancy
  • renal disease

Statistics from

Systemic lupus erythematosus (SLE) affects, particularly, women of childbearing age. Global SLE survival improvement due to better therapeutic management would lead to authorisation of pregnancy in an increased number of women. However, most studies analysing the relations between SLE and pregnancy found high fetal and maternal risks—notably, when pregnancy occurs in active SLE.1 In our 1987–91 French prospective study, SLE exacerbation was seen in 60% of the pregnancies and resulted in maternal death in 1.9% of the cases. Sixty three per cent of the newborn infants were premature, 29% growth retarded, and 5% died.2 Between 1982 and 1995 we prospectively “planned” 62 pregnancies in 38 women with SLE followed up in our department. Flares occurred in 27% of the cases. No child or mother died. After exclusion of early spontaneous and induced abortions, the live birth rate was 96%, which is close to that of the general French population.3

Nephritis is known to be one of the most serious complications of SLE and a strong predictor of poor outcome. However, its influence on mortality has decreased in recent studies,4 5 and a growing number of women with nephritis in the past wish to be pregnant. Our study aimed at analysing fetal and maternal courses and identifying risk factors in women with previous SLE nephritis in a tertiary referral centre. Fourteen planned and four non-planned pregnancies were included in previous global reports on SLE pregnancies.2 3

Patients and methods


Between 1982 and 1999 we followed up 32 pregnancies in 22 women with histologically proven SLE nephritis. Nephritis occurring after delivery was not taken into account. Thirteen women had one pregnancy, eight had two successive pregnancies, and one women had three. All patients fulfilled the 1997 American College of Rheumatology criteria for SLE.6 Antiphospholipid syndrome (APS) was diagnosed according to the recent criteria.7 Histological patterns of SLE nephritis were assessed by the 1995 WHO classification.8


We used the following definitions:

  • Embryonic loss: according to Branch's definition used in APS, spontaneous termination of pregnancy before 10 weeks' gestation9

  • Fetal death: death of a fetus shown to be alive at or beyond 10 weeks' gestation

  • Premature birth: termination of pregnancy with a live birth between weeks 21 and 37

  • Full term birth: termination of pregnancy with a live birth between 38 and 40 weeks

  • Intrauterine growth retardation: birth weight below the 10th centile for the stated gestation

  • Hypertension: diastolic pressure above 90 mm Hg

  • Pre-eclampsia: hypertension complicated with proteinuria or oedema, or both

  • Eclampsia: pre-eclampsia complicated with seizures or fitting

  • Adverse pregnancy outcome: at least three successive embryonic losses, therapeutic abortion, fetal or neonatal death.


Statistical analyses were carried out with a two sided Fisher's exact test.



Mean (SD) age at first pregnancy was 30 (4) years (range 18–35). One woman with sterility related to endometriosis had two consecutive induced pregnancies. Induction of ovulation was carried out with aspirin, hydroxychloroquine, and 15 mg prednisone daily. The first pregnancy was twin and occurred after the second cycle of in vitro fertilisation and embryo transfer. It spontaneously reduced to a singleton. The second pregnancy, occurring after in vitro fertilisation of a cryopreserved embryo, ended in embryonic loss. The other pregnancies were spontaneous.

At entry to the study, 11 women were nulliparous and 11 multiparous with 22 previous pregnancies. One multiparous women had had one previous fetal death related to APS. Five women had had seven normal pregnancies before SLE onset. Two women had a history of neonatal death. The other pregnancies led to embryonic losses (n=5), induced abortions for unwanted pregnancies (n=2) or for medical indication (n=5). Hence, fetal survival after exclusion of induced abortions was 7/15 (47%), but it was nil if only pregnancies occurring after SLE onset were taken into account (table 1).

Table 1

Outcome in 22 prior pregnancies in 11 women and 32 treated pregnancies in 22 women with past or present lupus nephritis. Values are shown as No (%)

Mean (SD) time between SLE diagnosis and pregnancy was 8 (5) years (maximum 18), and between renal disease onset and pregnancy was 6 (4) years (maximum 18). At pregnancy onset, SLE was known to be present in all patients except one, in whom SLE was diagnosed during the second trimester. The former patients had been previously treated with high dose prednisone, together with immunosuppressant drugs in eight women who had 12 pregnancies: oral cyclophosphamide during one year (n=1), azathioprine (n=2), and intravenous cyclophosphamide (n=9). Six pregnancies occurred in women treated with eight or fewer cyclophosphamide pulses, three in women treated with 11 pulses or more (maximum 18). Mean age at cyclophosphamide initiation was 25 (5) years (range 18–32). Eighteen pregnancies occurred in women previously treated with prednisone without immunosuppressant drugs. Two women with no previous renal disease developed nephrotic syndrome during pregnancy. One had known SLE, and postpartum renal biopsy disclosed diffuse proliferative glomerulonephritis. Pregnancy showed SLE in the other woman. Treatment consisted of high dose prednisone together with azathioprine. She died at 25 weeks from bacillus septicaemia. A postmortem examination disclosed diffuse proliferative glomerulonephritis.

Before pregnancy, with the exception of one woman with a creatine level of 107 μmol/l, all women had creatininaemia below 100 μmol/l, but the serum creatinine level had reached 100 μmol/l or more during previous renal flares in eight cases. Five women had proteinuria higher than 0.5 g/day, of whom one was nephrotic. None was treated for hypertension. Seventeen pregnancies occurred in women with antiphospholipid antibodies (aPL): anticardiolipin antibodies alone in 14 cases, lupus anticoagulant in six cases, of whom seven had APS. Eight pregnancies occurred in women with anti-SSA antibodies, associated with anti-SSB in two. None had a history of congenital atrioventricular block and none had received treatment to prevent it.


In addition to the case of SLE discovered during pregnancy, six other pregnancies were not planned. Three pregnancies occurred in women with active SLE: a proliferative glomerulonephritis was discovered a few months before pregnancy in two cases. A relapse with autoimmune haemolytic anaemia and nephrotic syndrome related to membranous glomerulonephritis appeared two months before pregnancy in the last case. Three pregnancies occurred in women with inactive SLE. One woman became pregnant a few weeks after her eighth monthly cyclophosphamide pulse and did not want an abortion. In the second case, nephrotic syndrome appeared while receiving 15 mg prednisone daily. Postpartum renal biopsy disclosed diffuse proliferative glomerulonephritis. In these cases, cyclophosphamide was stopped, the prednisone dose was increased to a mean of 25 mg/day (range 20–75). Low molecular weight heparin was started in two cases of nephrotic syndrome, together with aspirin in one case. Aspirin alone was prescribed in one case. Hydroxychloroquine was withdrawn in one case seen before 1995, started in one more recent pregnancy, and maintained in a third case.

In the last unplanned pregnancy in a woman with previous mesangial glomerulonephritis, diffuse proliferative glomerulonephritis occurred while receiving hydroxychloroquine two months after embryonic loss.


Twenty five pregnancies were planned as previously reported.3 Pregnancy was contraindicated when serum creatinine was above 130 μmol/l. Prior renal biopsies had shown mesangial glomerulonephritis (n=2), focal proliferative (n=4), diffuse proliferative (n=10), pure membranous glomerulonephritis (n=8), and focal segmental glomerulosclerosis (n=1). The last of these was considered to be specific to SLE because of a positive immunofluorescence study and corticosensitivity. Before pregnancy, three women were treated with hydroxychloroquine alone, 22 with prednisone (mean (SD) dose 10 (4.7) mg/day; range 5–20) alone or associated with antimalarial drugs in 10 cases. Upon pregnancy diagnosis, treatment with prednisone was started or its dose increased (mean 6 (10) mg/day). No treatment with immunosuppressant drugs was started. Hydroxychloroquine was withdrawn in two cases before 1995; after 1995 it was maintained in 11 cases. Aspirin was prescribed in 19 cases because of positive aPL or for eclampsia prevention, or both. Low molecular weight heparin was started in nine cases owing to a history of vascular thrombosis (n=5) or miscarriages under aspirin treatment (n=4), or both; it was associated with aspirin in nine cases. No therapeutic abortion was indicated.


Table 2 summarises the outcome of the 32 pregnancies. One feto-maternal death occurred. Twenty eight babies (two pairs of twins) were born: 15 boys and 13 girls.

Table 2

Outcome of pregnancies in women with SLE nephritis that occurred before, during pregnancy, or in the postpartum period

The outcome of six non-planned pregnancies was one embryonic loss, one fetal death, and four premature births (one twin pregnancy). Mean pregnancy duration was 32 (4) weeks (range 27–36). Average birth weight was 2200 (836) g (range 1250–2800). Caesarean section was indicated in one twin pregnancy. In one woman, ovarian cyst torsion was complicated by premature birth with neonatal death. One premature child remitted from perfringens neonatal infection. Pre-eclampsia occurred in a woman with APS followed up in 1982 and treated with prednisone without heparin or aspirin, leading to fetal death at six months.

The outcome of the 25 planned pregnancies was six full term births, 14 premature births (one twin), four embryonic losses, and one fetal death at 12 weeks' gestation in women with no clinical signs of SLE activity and no APS. Mean pregnancy duration was 33 (6) weeks (range 27–39) and average birth weight was 2722 (646) g (range 1000–3600). Caesarean section was carried out in six cases (five premature and one full term delivery). This was indicated by fetal distress in four cases, herpes zoster recurrence in one case, and ventricular shunt in one case. Five premature infants were growth retarded, and one had transient respiratory distress. The live birth rate was 24/32 (75%). Neonatal lupus, adrenal insufficiency, or congenital malformation were not seen.


We analysed the following indicators for live birth rate: planned pregnancy, SLE activity, serum creatinine, and proteinuria at pregnancy onset and during pregnancy, hypertension during pregnancy, presence of proliferative lesions on renal biopsy, presence of APS, aPL, anti-SSA antibodies, complement level at pregnancy onset, maximum corticosteroid dose during pregnancy, and use of heparin during pregnancy. No criterion reached statistical significance.


During pregnancy, proteinuria appeared in five women, in addition to the five women with known proteinuria. Proteinuria was related to pre-eclampsia in five pregnancies, associated with features of HELLP syndrome (haemolysis, elevated liver enzymes, low platelets) in one. Sudden hyperuricaemia and an abnormal obstetric ultrasound Doppler examination (notched uterine artery or raised resistance in umbilical artery, or both) were the initial signs. Serum complement was normal in three cases, decreased in two. DNA antibodies were negative in all cases. Three of these five pregnancies were planned. Three of the five occurred in APS with a history of vascular thrombosis. During pregnancy, treatment consisted of prednisone (mean maximum daily dose 27 (27) mg; range 10–75), associated with aspirin plus heparin (n=1), aspirin alone (n=2), or heparin alone (n=1), and one woman followed up in 1982 received neither heparin nor aspirin. Previous renal biopsy had disclosed diffuse proliferative glomerulonephritis in one case, focal proliferative glomerulonephritis in another, membranous glomerulonephritis in two, and focal glomerulosclerosis in the last. Fetal distress accompanied pre-eclampsia in four cases, leading to fetal death in one case. Caesarean section was indicated in three cases at 27–35 weeks and vaginal delivery was induced in one case at 31 weeks.

Nephrotic syndrome due to membranous glomerulonephritis remained stable during pregnancy and the postpartum period in one woman. Proteinuria was related to renal flare in four cases which occurred during the late second or the third trimester. SLE was diagnosed during one pregnancy. Two pregnancies were not planned pregnancies and two were planned. Two women had a history of glomerulonephritis, proliferative diffuse in one, mesangial in the other. Serum complement levels were low in all cases and DNA antibodies positive in three of four cases. This was disclosed by nephrotic syndrome in two cases. Hypertension was absent, but renal insufficiency appeared in one case (maximum serum creatinine 160 μmol/l). Histological examination disclosed diffuse proliferative glomerulonephritis in three cases (one postmortem, one postpartum, and one postabortum renal biopsy). The third woman with previous diffuse proliferative glomerulonephritis did not have a renal biopsy because the renal abnormalities remitted in the postpartum period.

Another SLE flare consisted of mild arthralgia not needing any treatment modification.

Two women with previous APS developed thromboembolic events: iliofemoral thrombophlebitis in one non-treated case in 1982, ovarian cyst torsion complicated by post-oophorectomy inferior vena caval thrombosis and pulmonary embolism, despite calcium heparin, in another case. The other maternal complications, present in three women, consisted of postpartum wall haematoma in a patient receiving both heparin and aspirin treatment, postpartum clostridium septicaemia, genital perfringens infection complicated by neonatal infection, and herpes zoster recurrence at delivery. No patient had an osteoporosis related fracture.

At long term follow up, one other patient died during an SLE flare when her child was four years old. Renal relapse occurred in three women in the subsequent one to two years: one women relapsed from diffuse proliferative glomerulonephritis, another woman with previous mesangial glomerulonephritis developed diffuse proliferative glomerulonephritis, and the last woman relapsed from focal glomerulosclerosis. All were treated with high dose prednisone and monthly cyclophosphamide pulses. In the other patients, SLE is fairly controlled by maintenance treatment with low dose prednisone or antimalarial drugs, or both. At the last visit, all women had creatininaemia below 120 μmol/l and one was treated for severe hypertension.



Studies on pregnancy outcome in women with past or current SLE nephritis are scarce. This may be explained, in part, by (a) the reduced fertility associated with long term cyclophosphamide10 or impaired renal function,11 or both, and (b) the classical assumption that pregnancy should be discouraged in women with a history of lupus nephritis. Of note, in our series, 13 pregnancies occurred in women previously treated with cyclophosphamide. Several studies have shown that the incidence of ovarian failure paralleled the increased age at cyclophosphamide initiation and cumulative dosage.10 12

In our study all the women had nearly normal renal function with pre-pregnancy serum creatinine below 100 μmol/l (that is, 0.8 mg/dl). At UCLA,11 38 pregnancies in 26 SLE women with normal or minimally impaired prepartum renal function (serum creatinine <90 μmol/l (<1 mg/dl), clearance >80 ml/min, proteinuria <1 g/day) ended in 10 abortions, whereas 14 pregnancies in 13 women with “mild” impairment (clearance 50–80 ml/min, proteinuria 1–3 g/day) ended in five abortions. Hence, the rate of successful pregnancy was 1.08 per woman with normal or minimally impaired renal function and decreased to 0.69 in case of mild renal impairment.

We noted that SLE flared up in five cases. However, the more severe aspect consisting of nephrotic syndrome was seen only in the non-planned pregnancies. Hence, the flare rate of SLE seems to be lower in a series including only women with SLE nephritis than in women with all patterns of SLE. In prospective studies conducted in referral centres,3 13-17 the SLE flare rate associated with pregnancy was around 60%. In a nephrological series including only women with SLE nephritis diagnosed before pregnancy, flare rates of 0% and 9% were found in the most recent studies,18 19probably because most pregnancies had begun when SLE was in remission. On the contrary, in the older studies including women with SLE nephritis diagnosed during pregnancy, higher flare rates, up to 81%,20-22 were seen (table 3).

Table 3

SLE and renal course in pregnancies with SLE nephritis

When renal anomaly appears during pregnancy in SLE, the crucial question remains the differentiation between SLE flare and pre-eclampsia. We noted this situation in six cases and we considered that in two cases it was related to pre-eclampsia favoured by previous nephropathy or aPL, because extra-renal manifestations of SLE and anti-DNA antibodies were absent. Serum complement was normal in three of five cases. In the four other cases we considered that it was an SLE renal flare with hypocomplementaemia or extra-renal manifestations, or both. DNA antibodies were positive in all renal flares but absent in the flare with only arthralgias. An increased corticosteroid dose improved both complement level and proteinuria. Of note, planning pregnancy does not exclude the risk of pre-eclampsia. Previous reports have shown that the usefulness of serum complement levels is variable.13 16 23 24 Complement activation may be present in pre-eclampsia, but its intensity is lower than in SLE. CH50 usually remains within or just below normal values in pre-eclampsia and complement split products tend to be only moderately raised. The CH50/Ba ratio can be interesting,25 but measurement of Ba is not routinely practised. Wong et al did not find any difference in serum C3 or C4 levels whether or not patients relapsed during pregnancy.13 Nossent and Swaak observed that fewer than half of the pregnancies with decreased serum C3 levels were associated with a clinical SLE flare.16 On the contrary, Shibata et al and Rubbertet al noted that hypocomplementaemia correlated with poor pregnancy outcome.23 24 Anti-dsDNA levels were also correlated with SLE activity.26

In our series, one feto-maternal death due to sepsis occurred in a case of diffuse proliferative glomerulonephritis disclosing SLE. In our French register on SLE pregnancy, we observed another death in similar conditions.2 Several studies have shown that active SLE glomerulonephritis, especially diffuse proliferative, has the worse prognosis. In the series of Imbasciati et al, two of four women developed postpartum or postabortum acute anuria and died from sepsis.21 This mortality may justify a therapeutic abortion, which has been carried out in up to 18% of pregnancies in SLE nephritis (table 2), but was not performed in our series.

Proteinuria became significant in one third of our patients and renal function worsened in 3%. Pre-eclampsia occurred in 16% of the pregnancies, more frequently when the pregnancy was unplanned, and led to rapid induced delivery, generally by caesarean section. No prolonged antihypertensive treatment was indicated. These renal anomalies were transient. Previous reports have shown a worsening of renal function in 11–27% of cases (table 3). This risk paralleled SLE activity: in the study of Hayslett and Lynn20 it was 10% when SLE was in remission at pregnancy onset, and it increased to 33% when SLE appeared during pregnancy. For SLE diagnosed before pregnancy, the risk of permanent renal deterioration seems low according to Oviasuet al 18 and Julkunenet al,19 but it should be noted that the latter included few cases of diffuse proliferative glomerulonephritis (table 3).


We observed a live birth rate of 75%. Previous reports have shown live birth rates ranging between 58 and 84% (table 2). However, the number of cases studied, the selection of data—including or not pregnancies occurring in active SLE, or SLE developing in the postpartum period, and the differential use of therapeutic abortions make comparisons difficult. In our series, after exclusion of embryonic losses, fetal survival rate in planned pregnancies was 92%, which is close to that observed in the French population and our global population of SLE planned pregnancies.3 In the series of Julkunen et al, including only inactive SLE at pregnancy onset, the live birth rate was 95.6%, but two therapeutic abortions had been performed.19 In the study of Hayslett and Lynn, 31 pregnancies occurred in women with inactive SLE, with seven therapeutic and three spontaneous abortions.20 In the series of Jungers et al, all pregnancies occurring in women with inactive SLE ended in live births, but this concerned only 11 pregnancies.22 Oviasuet al, including only women with inactive SLE, observed eight spontaneous abortions and one stillbirth among 47 pregnancies in SLE with previous nephritis.18 In these three studies the abortion date was not precisely known.

In our series, no criterion appeared to be a statistically significant indicator for fetal survival. SLE activity, hypertension, and the presence of APS were not indicators, but few patients had either of these manifestations. Major indicators of fetal outcome emerging in a series studying pregnancy outcome in SLE nephritis were SLE activity at pregnancy onset,20 22 severity of maternal renal disease,21 27 the presence of hypertension27or lupus anticoagulant,28 even if these criteria did not reach statistical significance in all series. Active renal disease was also a predictor of fetal loss.21 27

In conclusion, pregnancy need not be discouraged in women with SLE nephritis with normal or mildly impaired renal function. Deterioration of renal function rarely occurs when serum creatinine is below 100 μmol/l. However, these pregnancies are at high risk of pre-eclampsia and prematurity.


View Abstract

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.